Stockscreener 앱 받기
17.18
1.26%
-0.22
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Decreased by State Street Corp - MarketBeat
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - The Eastern Progress Online
XTX Topco Ltd Cuts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics' SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Canada
(TVTX) Investment Analysis - Stock Traders Daily
Y Intercept Hong Kong Ltd Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Fmr LLC Acquires 31,772 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics' SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Canada
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
Charles Schwab Investment Management Inc. Sells 1,184 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Two Sigma Advisers LP Increases Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lessened by Point72 Asia Singapore Pte. Ltd. - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Parkman Healthcare Partners LLC Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
HighVista Strategies LLC Decreases Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Bellevue Group AG Takes Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Walleye Capital LLC Has $6.83 Million Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Purchases 228,300 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics' SVP Calvin Sandra sells $221,257 in stock By Investing.com - Investing.com Nigeria
Travere Therapeutics' SVP Calvin Sandra sells $221,257 in stock - Investing.com India
Travere Therapeutics to Present at Evercore and Citi Healthcare Conferences in December | TVTX Stock News - StockTitan
Connor Clark & Lunn Investment Management Ltd. Increases Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Oppenheimer & Co. Inc. Buys Shares of 48,139 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices
Travere: Q3 Earnings Snapshot - AOL
Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
3 Under-the-Radar Healthcare Companies - MSN
When (TVTX) Moves Investors should Listen - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com
Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail
Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times
2.88%
2.65%
자본화:
|
볼륨(24시간):